137 related articles for article (PubMed ID: 31560127)
1. Metabolic syndrome affects the long-term survival of patients with non-endometrioid carcinoma of the uterine corpus.
Shou H; Yan K; Song J; Zhao L; Zhang Y; Ni J
Int J Gynaecol Obstet; 2020 Jan; 148(1):96-101. PubMed ID: 31560127
[TBL] [Abstract][Full Text] [Related]
2. Clinical predictors of long-term survival for stage IVB uterine papillary serous carcinoma confined to the abdomen.
Lee LJ; Demaria R; Berkowitz R; Matulonis U; Viswanathan AN
Gynecol Oncol; 2014 Jan; 132(1):65-9. PubMed ID: 24211401
[TBL] [Abstract][Full Text] [Related]
3. Uterine papillary serous, clear cell, and poorly differentiated endometrioid carcinomas: a comparative study.
Greggi S; Mangili G; Scaffa C; Scala F; Losito S; Iodice F; Pisano C; Montoli S; Viganò R; Pirozzi G; Giannarelli D
Int J Gynecol Cancer; 2011 May; 21(4):661-7. PubMed ID: 21412164
[TBL] [Abstract][Full Text] [Related]
4. Comparative Survival Outcomes of Uterine Papillary Serous Carcinoma, Clear Cell Carcinoma, Grade 3 Endometrioid Adenocarcinoma, and Carcinosarcoma of Endometrial Cancer in Rajavithi Hospital.
Prueksaritanond N; Chantape W
J Med Assoc Thai; 2016 Feb; 99 Suppl 2():S75-83. PubMed ID: 27266220
[TBL] [Abstract][Full Text] [Related]
5. Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison.
Zhang C; Hu W; Jia N; Li Q; Hua K; Tao X; Wang L; Feng W
Int J Gynecol Cancer; 2015 May; 25(4):629-36. PubMed ID: 25633654
[TBL] [Abstract][Full Text] [Related]
6. Uterine papillary serous carcinoma pre-operatively diagnosed as endometrioid carcinoma: Is omentectomy necessary?
Peled Y; Aviram A; Krissi H; Gershoni A; Sabah G; Levavi H; Eitan R
Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):498-502. PubMed ID: 26235227
[TBL] [Abstract][Full Text] [Related]
7. Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference?
Boruta DM; Gehrig PA; Groben PA; Bae-Jump V; Boggess JF; Fowler WC; Van Le L
Cancer; 2004 Nov; 101(10):2214-21. PubMed ID: 15452833
[TBL] [Abstract][Full Text] [Related]
8. Comparison of outcomes in early-stage uterine clear cell carcinoma and serous carcinoma.
Zhang M; Yang TJ; Desai NB; DeLair D; Kollmeier MA; Makker V; Leitao MM; Abu-Rustum NR; Alektiar KM
Brachytherapy; 2019; 18(1):38-43. PubMed ID: 30316723
[TBL] [Abstract][Full Text] [Related]
9. Improved long-term survival of corpus cancer in Japan: A 40-year population-based analysis.
Yagi A; Ueda Y; Ikeda S; Miyoshi A; Nakagawa S; Hiramatsu K; Kobayashi E; Kimura T; Ito Y; Nakayama T; Nakata K; Morishima T; Miyashiro I; Kimura T
Int J Cancer; 2022 Jan; 150(2):232-242. PubMed ID: 34494658
[TBL] [Abstract][Full Text] [Related]
10. Poor prognosis of uterine serous carcinoma compared with grade 3 endometrioid carcinoma in early stage patients.
Park JY; Nam JH; Kim YT; Kim YM; Kim JH; Kim DY; Sohn I; Lee SW; Sung CO; Kim KR
Virchows Arch; 2013 Mar; 462(3):289-96. PubMed ID: 23417747
[TBL] [Abstract][Full Text] [Related]
11. Optimal cytoreduction, depth of myometrial invasion, and age are independent prognostic factors for survival in women with uterine papillary serous and clear cell carcinomas.
Solmaz U; Mat E; Ekin A; Gezer C; Biler A; Peker N; Ayaz D; Sanci M
Int J Surg; 2016 Aug; 32():71-7. PubMed ID: 27365052
[TBL] [Abstract][Full Text] [Related]
12. Survival after stage IA endometrial cancer; can follow-up be altered? A prospective nationwide Danish survey.
Lajer H; Elnegaard S; Christensen RD; Ortoft G; Schledermann DE; Mogensen O
Acta Obstet Gynecol Scand; 2012 Aug; 91(8):976-82. PubMed ID: 22548255
[TBL] [Abstract][Full Text] [Related]
13. Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study.
Winder AD; Maniar KP; Wei JJ; Liu D; Scholtens DM; Lurain JR; Schink JC; Buttin BM; Filiaci VL; Lankes HA; Ramirez NC; Park K; Singh M; Lieberman RW; Mannel RS; Powell MA; Backes FJ; Mathews CA; Pearl ML; Secord AA; Peace DJ; Mutch DG; Creasman WT; Kim JJ
Cancer; 2017 Apr; 123(7):1144-1155. PubMed ID: 27926776
[TBL] [Abstract][Full Text] [Related]
14. Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer.
Santin AD; Bellone S; Siegel ER; Palmieri M; Thomas M; Cannon MJ; Kay HH; Roman JJ; Burnett A; Pecorelli S
Am J Obstet Gynecol; 2005 Mar; 192(3):813-8. PubMed ID: 15746676
[TBL] [Abstract][Full Text] [Related]
15. Impact of Chemotherapy and Radiotherapy on Management of Early Stage Clear Cell and Papillary Serous Carcinoma of the Uterus.
Hong JC; Foote J; Broadwater G; Gaillard S; Havrilesky LJ; Chino JP
Int J Gynecol Cancer; 2017 May; 27(4):720-729. PubMed ID: 28375927
[TBL] [Abstract][Full Text] [Related]
16. Early-stage Uterine Pure and Mixed Clear Cell Carcinoma: Outcomes and Recurrence With and Without Adjuvant Therapy.
Chang-Halpenny CN; Natarajan S; Hwang-Graziano JM
Am J Clin Oncol; 2018 Apr; 41(4):371-378. PubMed ID: 26950465
[TBL] [Abstract][Full Text] [Related]
17. Trends in Survival of Patients With Uterine Serous Carcinoma From 1988 to 2011: A Population-Based Study.
Mahdi H; Han X; Moulton L; Vargas R
Int J Gynecol Cancer; 2017 Jul; 27(6):1155-1164. PubMed ID: 28562471
[TBL] [Abstract][Full Text] [Related]
18. Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer.
Hoogendoorn WE; Hollema H; van Boven HH; Bergman E; de Leeuw-Mantel G; Platteel I; Fles R; Nederlof PM; Mourits MJ; van Leeuwen FE;
Breast Cancer Res Treat; 2008 Nov; 112(1):99-108. PubMed ID: 18064567
[TBL] [Abstract][Full Text] [Related]
19. Long-term survival in uterine clear cell carcinoma and uterine papillary serous carcinoma.
Lindahl B; Persson J; Ranstam J; Willén R
Anticancer Res; 2010 Sep; 30(9):3727-30. PubMed ID: 20944161
[TBL] [Abstract][Full Text] [Related]
20. Uterine Papillary Serous Carcinoma: A Single-Institution Review of 62 Cases.
Black C; Feng A; Bittinger S; Quinn M; Neesham D; McNally O
Int J Gynecol Cancer; 2016 Jan; 26(1):133-40. PubMed ID: 26588230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
